Inactive Instrument

Intervacc AB Share Price Nasdaq Stockholm

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm Other stock markets
- ^SEK	-

31/07	Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac	CI
30/07	Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration	MT

Analysts' recommendations: Intervacc AB

20/24/20	Penser reiterates motivated value for Intervacc - report met expectations	FW
21/24/21	Penser lowers Intervacc's motivated value	FW
17/23/17	Penser makes minor estimate adjustments in Intervacc	FW
04/23/04	Penser lowers its motivated value for Intervacc to SEK 26-28 (48-54)	FW
20/23/20	Penser halves the motivated value for Intervacc - which falls on the stock exchange	FW

More recommendations

Managers and Directors: Intervacc AB

Manager	Title	Age	Since
Carl-Johan Dalsgaard CEO	Chief Executive Officer	70	05/02/2026
Jan Persson DFI	Director of Finance/CFO	-	06/02/2020
Andrew Waller CTO	Chief Tech/Sci/R&D Officer	-	11/06/2020

Director	Title	Age	Since
Emil Billbäck CHM	Chairman	56	13/05/2026
Carl Erik Mathias Uhlén BRD	Director/Board Member	72	01/01/2024
Björn Ingemar Odlander BRD	Director/Board Member	68	01/01/2025

More insiders

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâ€™s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Employees

Sector

Biotechnology & Medical Research

Calendar

20/08 Earnings release - Q2 2026

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	43Cr 4.54Cr 3.95Cr 3.67Cr 3.37Cr 6.37Cr 433.22Cr 6.47Cr 17Cr 215.67Cr 17Cr 17Cr 723.19Cr	P/E 2026 *	-5.77x	P/E 2027 *	-5.77x
Enterprise Value	34Cr 3.56Cr 3.1Cr 2.88Cr 2.65Cr 5Cr 340.09Cr 5.08Cr 13Cr 169.31Cr 13Cr 13Cr 567.72Cr	EV / Sales 2026 *	19.2x	EV / Sales 2027 *	12.3x
Free-Float	80.66%	Yield 2026 *	-	Yield 2027 *	-

31/07	Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac	CI
30/07	Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration	MT
29/07	Intervacc Gets Special Approval to Send Equine Vaccine to New Zealand	MT
29/07	Intervacc AB Publ Makes First Export Of Strangvac To New Zealand Under Special Circumstances Permit	CI
22/05	Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials	CI
15/05	Sweden's Intervacc Elects New Chair	MT
15/05	Appoints Emil Billbäck as chairman	RE
13/05	Intervacc elects Emil Billbäck as chairperson of board	RE
13/05	Intervacc AB Announces Board Changes	CI
13/05	Intervacc Q1 net sales down at SEK 3.4 million	RE
13/05	Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
12/05	Intervacc AB Announces Appointment of Lars Stubberud as Chief Technology Officer, Effective July 15, 2026	CI
16/04	Intervacc: Strangvac vaccine approved in Iceland	RE

30/07	Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac	AQ
29/07	Intervacc: New Zealand order validates Strangvac’s position	AQ
29/07	Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit	AQ
04/06	Redeye initiates coverage of Intervacc	AQ
22/05	Intervacc: Positive results	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+2.35%	+2.74%	+38.10%	+74.02%	5.65TCr
ARGENX SE	-3.09%	-6.51%	+25.66%	+62.29%	5.36TCr
BIONTECH SE	-1.24%	+1.40%	-15.61%	-13.72%	2.29TCr
INSMED INCORPORATED	-0.25%	-7.78%	-9.28%	+352.92%	2.14TCr
WUXI BIOLOGICS (CAYMAN) INC.	+0.15%	+0.36%	+24.28%	-14.44%	2.03TCr
GENMAB A/S	-1.51%	-2.28%	+31.86%	-29.13%	1.76TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.45%	-7.15%	+17.96%	+554.50%	1.47TCr
PHARMAESSENTIA CORPORATION	+3.41%	-6.61%	+162.81%	+287.77%	1.35TCr
EXELIXIS, INC.	-1.03%	-4.23%	+42.32%	+160.72%	1.33TCr
Average	-0.14%	-3.79%	+35.34%	+159.44%	2.6TCr
Weighted average by Cap.	+0.02%	-2.96%	+30.18%	+120.42%

	2026 *	2027 *
Net sales	1.77Cr 18.56L 16.13L 15.02L 13.79L 26.03L 18Cr 26.44L 69.47L 8.82Cr 69.7L 68.17L 30Cr	3Cr 31.51L 27.39L 25.49L 23.41L 44.2L 30Cr 44.88L 1.18Cr 15Cr 1.18Cr 1.16Cr 50Cr
Net income	-8.08Cr -84.72L -73.65L -68.55L -62.94L -1.19Cr -81Cr -1.21Cr -3.17Cr -40Cr -3.18Cr -3.11Cr -135Cr	-8.36Cr -87.71L -76.24L -70.97L -65.15L -1.23Cr -84Cr -1.25Cr -3.28Cr -42Cr -3.29Cr -3.22Cr -139.77Cr
Net Debt	-9.3Cr -97.56L -84.81L -78.94L -72.48L -1.37Cr -93Cr -1.39Cr -3.65Cr -46Cr -3.66Cr -3.58Cr -155.47Cr	-6.3Cr -66.05L -57.42L -53.45L -49.07L -92.67L -63Cr -94.1L -2.47Cr -31Cr -2.48Cr -2.43Cr -105.26Cr

Intervacc AB Share Price Nasdaq Stockholm

Stocks

Biotechnology & Medical Research

Valuation: Intervacc AB

Latest news : Intervacc AB

Analysts' recommendations: Intervacc AB

Press Releases: Intervacc AB

Managers and Directors: Intervacc AB

Bio Therapeutic Drugs

Financials

Company Profile